Is it a good time to buy ACB stock based on its recent increase?

**Bottom-line 🚦:** ACB’s recent pop looks more like a short-term bounce than the start of a durable up-trend, so the risk-reward still skews toward *waiting for a pull-back* rather than jumping in fresh. 📉➡️📈 --- ### 1. Momentum is wobbling 🤔 • Over the last two weeks ACB has swung from –6.2 % on 3/03 to +4.9 % on 3/04 and has slipped –2.23 % on 3/12 and –2.28 % on 3/13, showing a classic “dead-cat” pattern of sharp but unsustainable moves. |market_code|code|Ticker|Name|Date|Percentage Change| |---|---|---|---|---|---| |186|ACB|ACB.O|Aurora Cannabis|20260311|1.412429| • Even the pre- and post-market prints (+1.14 % and +0.87 %) are small and fail to break the larger down-trend. |market_code|code|Ticker|Name|Date|Post-Market Percentage Change|Pre-Market Percentage Change| |---|---|---|---|---|---|---| |186|ACB|ACB.O|Aurora Cannabis|20260313|0.8746|1.1396| --- ### 2. Fundamentals: a mixed bag 🧩 | Positive | Negative | |---|---| | Canaccord just initiated coverage at C$10, citing ACB’s medical-first pivot and 10-15 % revenue growth guide for FY-26. | Q3-26 EPS miss was brutal (-89 %) and the stock still trades at a negative P/E (-3.50). | | Strong balance sheet: C$154 M cash, zero cannabis-related debt, and a fresh ATM for up to C$100 M. | Options market is pricing a “big move” amid falling analyst estimates—classic sign of elevated uncertainty. | --- ### 3. Macro & sector headwinds 🌪️ • Broader equity markets are under pressure: the S&P 500 just logged its worst week since October, and the NASDAQ its second-worst, reflecting rising rates and geopolitical jitters. • Cannabis remains a high-beta, regulation-sensitive niche; SNDL’s cautionary note that ACB “trades at about the same multiple” as its peer underscores valuation risk. --- ### 4. Technical read 📊 • Price sits well below the 50- and 200-day SMAs (C$5.64 & C$6.51) and RSI hovers near oversold territory, suggesting room for a relief rally but also highlighting how far it still is from trend support. • Candlestick analysis shows only *intraday* bullish patterns (e.g., morning doji star on 3/06) that have yet to translate into a sustained breakout. --- ### 5. Actionable takeaways 🎯 1. **Patience pays:** Given the choppy price action and weak EPS history, consider scaling in only on deeper pull-backs toward the C$3.00–C$3.25 zone, where risk/reward improves. 2. **Tight risk controls:** If you do enter, pair ACB with a steadier energy name (e.g., Coterra) to buffer volatility—something your profile already values. 3. **Catalyst watch:** Monitor Q4 results (expected late May) and any updates on the Canadian medical reimbursement debate that ACB is actively lobbying. --- Ready to let the market cool off a bit more, or would you like a quick screen for other cannabis names that might offer a cleaner entry? 🌱📈